Treatment method and prognostic factors of chondrosarcoma: based on Surveillance, Epidemiology, and End Results (SEER) database

Background Chondrosarcoma is a malignant tumor originating from cartilage tissue. It is the second most malignant bone tumor, accounting for about 10% to 15% of all primary bone tumors. So far, there have been no reports of large-scale clinical statistics on the relationship between non-surgical treatment and prognosis in patients with chondrosarcoma. Methods Through the search of the Surveillance, Epidemiology, and End Results (SEER) database, chondrosarcoma patients registered between January 1, 2004 and December 31, 2016 were selected as research goals. Univariate analysis of overall survival (OS) and chondrosarcoma-specific survival (CSSS) by Kaplan-Meier survival analysis and log-rank test. Mapping Kaplan-Meier curves for prognostic factors that are significant for OS and CSSS in patients with chondrosarcoma. After univariate analysis, the prognostic factors that have a significant effect on the prognosis were included in the multivariate Cox regression analysis, and the independent factors that affected the prognosis were screened. Results A total of 1,128 patients with chondrosarcoma were included in the study. Univariate analysis showed that prognostic factors such as age, gender, primary site, histological type, grade, tumor size, metastasis, surgery, radiotherapy, chemotherapy and treatment method had significant effects on all-cause mortality (ACM) and chondrosarcoma-specific mortality (CSSM). These factors were included in the multivariate Cox regression analysis. The results showed age, primary site, histological type, grade, tumor size, metastasis, and treatment method were independent factors affecting ACM and CSSM. Conclusions This study found that although non-surgical treatment of chondrosarcoma has made great progress, at present, it is still not considered that non-surgical treatment can significantly improve the prognosis. There are many factors affecting the prognosis of chondrosarcoma, including age, primary site, histological type, grade, tumor size, distant metastasis and treatment method. In the future, more samples and more detailed data will be needed to study the treatment of chondrosarcoma and to analyze the important factors affecting prognosis through big data analysis.

[1]  D. Campanacci,et al.  Conventional Primary Central Chondrosarcoma of the Pelvis: Prognostic Factors and Outcome of Surgical Treatment in 162 Patients , 2018, The Journal of bone and joint surgery. American volume.

[2]  S. Kliethermes,et al.  Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001‐2011) , 2017, Journal of surgical oncology.

[3]  M. Dominkus,et al.  Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry , 2011, International Orthopaedics.

[4]  P. Choong,et al.  Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion. , 2010, Biochemical and biophysical research communications.

[5]  O. P. Camargo,et al.  Chondrosarcoma of Bone: Lessons From 46 Operated Cases in a Single Institution , 2010, Clinical orthopaedics and related research.

[6]  Wei Guo,et al.  Surgical treatment of pelvic chondrosarcoma involving periacetabulum , 2010, Journal of surgical oncology.

[7]  L. Koniaris,et al.  Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. , 2009, The Journal of bone and joint surgery. American volume.

[8]  L. Dodd,et al.  The Clinical Management of Chondrosarcoma , 2009, Current treatment options in oncology.

[9]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[10]  W. Chow.  Update on chondrosarcomas , 2007, Current opinion in oncology.

[11]  S. Sel,et al.  Differential expression of VEGF‐A and angiopoietins in cartilage tumors and regulation by interleukin‐1β , 2006, Cancer.

[12]  F. Böhler,et al.  Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. , 2006, Anticancer research.

[13]  M. Horodyski,et al.  Grade 2 Chondrosarcoma: Stage I or Stage II Tumor? , 2003, Clinical orthopaedics and related research.

[14]  A. Wilson,et al.  From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[16]  G. Cooper,et al.  Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.

[17]  F. Sim,et al.  Chondrosarcoma of the Pelvis: A Review of Sixty-four Cases , 2001, The Journal of bone and joint surgery. American volume.

[18]  J. Harrelson,et al.  Chondrosarcoma of Bone: Analysis of 108 Cases and Evaluation for Predictors of Outcome , 2001, Clinical orthopaedics and related research.

[19]  J. Bruns,et al.  Chondrosarcoma of bone: an oncological and functional follow-up study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  H J Mankin,et al.  Chondrosarcoma of bone: an assessment of outcome. , 1999, The Journal of bone and joint surgery. American volume.

[21]  D. Ilstrup,et al.  Primary chondrosarcoma of long bones and limb girdles , 1998, Cancer.

[22]  A. Yasko,et al.  Chondrosarcoma of the pelvis: Prognostic factors for 67 patients treated with definitive surgery , 1996, Cancer.

[23]  C. Beauchamp.  Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database , 2010 .

[24]  J. D. de Rooy,et al.  Cryosurgery in aggressive, benign, and low-grade malignant bone tumours. , 2005, The Lancet. Oncology.

[25]  R. Grimer,et al.  Risk factors for survival and local control in chondrosarcoma of bone. , 2002, The Journal of bone and joint surgery. British volume.